title: Sense and non-sense of polypharmacy: increasing efficacy, decreasing compliance?
authors.affiliation: Hôpital de la Salpétrière, Pavillon Clérambault, UMR 7593 CNRS, Paris 75013, France. paboyer@ext.jussieu.fr
authors.forename: Patrice
authors.initials: P
authors.lastname: Boyer
mesh_terms: D000203:Activities of Daily Living / Q000523:psychology; D000465:Algorithms; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001526:Behavioral Symptoms / Q000188:drug therapy* / Q000209:etiology; D003071:Cognition / Q000187:drug effects; D019468:Disease Management; D004347:Drug Interactions; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000379:methods / Q000523:psychology; D006801:Humans; D055118:Medication Adherence / Q000523:psychology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000517:prevention & control; D019338:Polypharmacy; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D014150:Antipsychotic Agents